Aristo Bio-Tech And Lifescience Limited (ARISTO)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Aristo Bio-Tech's revenue was ₹107 Cr (+2.9% year on year, -58.2% on the previous half-year), and net profit ₹3.0 Cr; the operating margin was 7.5%.
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹107 | +2.9% | -58.2% |
| Operating profit | ₹8.0 | +700.0% | +0.0% |
| Net profit | ₹3.0 | — | -25.0% |
| EPS (₹) | 4.42 | from loss | -27.9% |
| Operating margin | 7.5% | — | — |
ARISTO delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 100.0% of the ARISTO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 100.0%. That is close to its usual level. Turnover was only ₹1 lakh, so a handful of trades can move this figure. It closed at its lower price band (circuit) on 16 Oct, one of 6 band closes in about the last 20 sessions.
Delivery in the last 5 sessions: 100.0% · 100.0% · 100.0% · 100.0% · 100.0%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Aristo Bio-Tech and Lifescience Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing covers the quarter ended September 30, 2026, confirmed by Registrar and Share Transfer Agent MUFG Intime India Private Limited. The RTA verified that physical share certificates received for dematerialisation were properly processed, accepted/rejected, and mutilated or cancelled. This is a standard quarterly administrative filing with no operational or financial impact.
- Compliance certificate submitted under Regulation 74(5) of SEBI Regulations, 2018
- Pertains to the quarter ended September 30, 2026
- Issued by RTA MUFG Intime India Private Limited on October 03, 2026
Aristo Bio-Tech and Lifescience Limited submitted the voting results and Scrutinizer's Report for its 21st Annual General Meeting held on September 30, 2026. A total of 55,44,600 votes were polled, representing 81.44% of the total 68,07,800 outstanding shares. All presented resolutions, including adoption of financial statements, final dividend declaration, and director re-appointments, passed with 100% of votes in favour. No invalid or dissenting votes were registered.
- Total votes polled stood at 55,44,600, accounting for 81.44% of total outstanding shares (68,07,800)
- Promoter group polled 100% of its 49,98,200 shares, while public non-institutions polled 5,46,400 shares (30.19%)
- 100% of the polled votes across all items were cast in favour, with 0 votes against
- Total 9 resolutions were passed during the 21st AGM held via video conferencing
Aristo Bio-Tech and Lifescience Limited has dispatched the web-link for its FY 2025-26 Annual Report to shareholders without registered email addresses, under SEBI Regulation 36(1)(b). The company announced its 21st Annual General Meeting (AGM) will take place virtually on September 30, 2026, at 04:00 PM IST. The cut-off date to determine e-voting eligibility is set for September 23, 2026. Remote e-voting opens on September 27, 2026, and concludes on September 29, 2026.
- 21st AGM scheduled for September 30, 2026, at 04:00 P.M. (IST) via Video Conferencing
- Cut-off date for e-voting eligibility set for September 23, 2026
- Remote e-voting window runs from September 27, 2026 (9:00 AM) to September 29, 2026 (5:00 PM)
- Filing made pursuant to SEBI Listing Regulation 36(1)(b) for unregistered email holders
Aristo Bio-Tech And Lifescience Limited has issued the notice for its 21st Annual General Meeting scheduled for September 30, 2026. Key agenda items include the declaration of a final dividend of Rs 0.60 per equity share (face value Rs 10) for FY26. Shareholders will also vote on the re-appointment and remuneration revision of Whole Time Director Ketankumar Harkantbhai Joshi and Executive Director Kusum Narendra Singh Barhat to Rs 5,00,000 per month each (up from Rs 33,50,000 per annum). E-voting will take place from September 27 to September 29, 2026.
- 21st AGM scheduled for September 30, 2026, via Video Conferencing
- Final dividend proposed at Rs 0.60 per equity share of Rs 10 each for FY26
- Proposed remuneration of Rs 5,00,000 per month for Whole Time Director Ketankumar Joshi and Executive Director Kusum Barhat (previously Rs 33,50,000 p.a.)
- E-voting begins at 9:00 a.m. on September 27, 2026, and concludes at 5:00 p.m. on September 29, 2026
Aristo Bio-Tech and Lifescience Limited has fixed Wednesday, September 23, 2026, as the record date for its final dividend of ₹0.60 per equity share (face value ₹10) for FY26. The 21st Annual General Meeting is scheduled for September 30, 2026, via video conferencing to approve the dividend and other resolutions. The board also recommended the re-appointment of Mr. Ketankumar Harkantbhai Joshi as Whole Time Director and Ms. Rashmi Kamlesh Otavani as Independent Director for 5-year terms starting March 2027.
- Fixed September 23, 2026, as the record date for final dividend of ₹0.60 per share of face value ₹10
- Scheduled 21st AGM for September 30, 2026, at 04:00 PM IST via video conferencing
- Re-appointment of Whole Time Director Ketankumar Harkantbhai Joshi for 5 years effective March 20, 2027
- Re-appointment of Non-Executive Independent Director Rashmi Kamlesh Otavani for 5 years effective March 20, 2027
- Appointed M/s Y.S. Thakar & Co. as Cost Auditor for FY 2026-27
Aristo Bio-Tech and Lifescience Limited held its Board Meeting on September 07, 2026, fixing Wednesday, September 23, 2026, as the record date for a final dividend of ₹0.60 per equity share (face value ₹10) for FY 2025-26. The Board also approved the re-appointment of Mr. Ketankumar Harkantbhai Joshi as Whole Time Director and Ms. Rashmi Kamlesh Otavani as Non-Executive Independent Director, both for 5-year terms beginning March 20, 2027, subject to shareholder approval. Additionally, the 21st AGM is scheduled for September 30, 2026, and M/s Y.S. Thakar & Co. was appointed as the Cost Auditor for FY 2026-27.
- Final dividend of ₹0.60 per equity share of face value ₹10 fixed for FY 2025-26
- Record date for dividend eligibility set as Wednesday, September 23, 2026
- 21st Annual General Meeting to be held via VC/OAVM on September 30, 2026
- Re-appointment of Whole Time Director and Independent Director approved for 5 years from March 20, 2027, to March 19, 2032
- Appointment of M/s Y.S. Thakar & Co. as Cost Auditor for FY 2026-27 approved
Financial Performance
Revenue Growth by Segment
The company operates in a single segment (Agrochemicals). Revenue from operations for the half-year ended September 30, 2025, reached INR 256.45 Cr, representing a 19.75% growth compared to INR 214.15 Cr in the same period of the previous year. Full-year revenue for FY25 was INR 318.09 Cr.
Profitability Margins
Net Profit Margin declined by 29% from 1.48% in FY24 to 1.06% in FY25. For the half-year ended September 30, 2025, the company reported a Profit Before Tax of INR 5.54 Cr, a decrease from INR 6.07 Cr in the corresponding previous half-year.
EBITDA Margin
Not explicitly disclosed, but Net Profit Margin stood at 1.06% for FY25. Operating efficiency is reflected in the Net Capital Turnover Ratio, which improved by 22% to 5.23 in FY25, indicating more efficient use of short-term assets to support sales.
Credit Rating & Borrowing
The Debt Equity Ratio improved by 6%, decreasing from 0.62 in FY24 to 0.59 in FY25 due to a reduction in total debt. Finance costs for the half-year ended September 30, 2025, were INR 1.05 Cr.
Operational Drivers
Raw Materials
Agrochemical technicals used for manufacturing Fungicides, Herbicides, Weedicides, and Insecticides. Cost of materials consumed in FY25 was INR 295.60 Cr, representing 92.9% of total revenue.
Raw Material Costs
Raw material costs accounted for 92.9% of revenue in FY25 (INR 295.60 Cr). For the half-year ended September 30, 2025, material costs were INR 239.42 Cr, up from INR 197.02 Cr in the previous year's corresponding period, reflecting a 21.5% increase in procurement costs.
Manufacturing Efficiency
Manufacturing efficiency is indicated by the Inventory Turnover Ratio, which improved by 5% from 6.91 in FY24 to 7.27 in FY25, suggesting faster movement of agrochemical stocks.
Strategic Growth
Expected Growth Rate
19.75%
Growth Strategy
Growth is pursued through a focus on human resource development (66 full-time employees) and improving HR policies to enhance organizational performance. Strategically, the company is improving its operational cycle, evidenced by a 16% improvement in the Trade Receivable Turnover Ratio (5.60 in FY25), which ensures faster cash realization to fund the production of Fungicides and Insecticides.
Products & Services
Fungicides, Herbicides, Weedicides, and Insecticides.
External Factors
Industry Trends
The agrochemical industry is evolving with shifting regulatory requirements and market needs for crop protection. Aristo is positioned as a specialized player in Fungicides and Herbicides, maintaining a focus on efficient capital use to navigate these shifts.
Competitive Moat
The company's moat is built on operational efficiency and strong internal controls. The 22% increase in the Net Capital Turnover Ratio and a 16% improvement in receivable collections suggest a sustainable advantage in managing working capital compared to peers with slower cycles.
Macro Economic Sensitivity
The company is sensitive to agricultural market dynamics and regulatory changes affecting the agrochemical sector.
Consumer Behavior
Demand is driven by agricultural cycles and the need for effective pest and weed control in farming.
Regulatory & Governance
Industry Regulations
The company complies with the Companies Act, 2013, and is exempt from certain SEBI LODR corporate governance regulations (Regulations 17 to 27) due to its listing on the SME Exchange and having a paid-up capital below INR 10 Cr and net worth below INR 25 Cr.
Taxation Policy Impact
The company reported a deferred tax liability increase of INR 0.28 Cr for the half-year ended September 30, 2025. The effective tax rate for FY25 was approximately 25.7% based on a PBT of INR 5.47 Cr and PAT of INR 4.06 Cr.
Legal Contingencies
The company reported no long-term contracts, including derivative contracts, with material foreseeable losses. There were no amounts required to be transferred to the Investment Education and Protection Fund.
Risk Analysis
Key Uncertainties
Key risks include the potential for material misstatement due to fraud or error, which the company mitigates through an internal financial control system that auditors have deemed adequate and effective.
Technology Obsolescence Risk
The company uses accounting software with audit trail (edit log) facilities to ensure the integrity of financial records and mitigate digital risks.
Credit & Counterparty Risk
Credit risk is managed through efficient collection processes, resulting in a 16% improvement in the Trade Receivable Turnover Ratio to 5.60 in FY25.
